Search Tag: evolocumab

Cardiology Management

Esccongress-findings-from-the-evopacs-study

2019 31 Aug

Despite the fact that guidelines recommend the initiation of high-intensity statin therapy in patients with acute coronary syndrome (ACS), target levels are not achieved in a large number of patients. Evolocumab, a rapidly acting, low-density lipoprotein cholesterol (LDL-C) Lowering drug had so far not been studied in the acute phase of acute coronary...Read more

Cardiology Management

Low-utilisation-of-new-cholesterol-drugs

2017 03 Oct

Cholesterol lowering medications PCSK9 inhibitors (PCSK9i), alirocumab and evolocumab, were approved in 2015. Their high cost however has led to strict prior authorisation practices and high copays, curtailing use of PSCK9i in clinical practice, according to a new study published by JAMA Cardiology. PCSK9 inhibitors are typically prescribed by doctors...Read more